Post-Market Safety Updates Replaced By “Periodic Benefit-Risk Evaluation Reports”
This article was originally published in The Pink Sheet Daily
Executive Summary
Draft guidance from FDA would adopt the International Conference on Harmonization’s periodic benefit-risk evaluation reports, which will offer sponsors the opportunity to provide updates on benefit information along with safety signals to the regulatory authorities.
You may also be interested in...
Harmonization Fail: ICH Guideline Doesn’t Simplify Safety Reporting, Firms Say
Crucially, the synchronization of landmark dates and reporting periods seems not to have been resolved by publication of the FDA/ICH document.
FDA Pushes Back Against “Living” Benefit-Risk Assessment Management Plan
The Institute of Medicine urges the agency to create a publicly available document setting forth benefits and risks of drugs, with periodic updates, but FDA says it has no extra resources to handle such an effort.
Not Another FDAAA – Observers Expect Fewer FDA Reforms In PDUFA V
Congress is not expected to pile as many new responsibilities on FDA in the upcoming Prescription Drug User Fee Act reauthorization as in 2007’s FDA Amendments Act.